BMI is B-A-D, a new study suggests. Here's a better way to measure weight
When it comes to measuring weight, BMI is the acronym everyone loves to hate. Health professionals have long used body mass index as a quick screening tool to fast-track certain patients into a 'code red' management plan — people whose weight puts them in danger of future health problems.
The issue is that BMI measures health risk by calculating height and weight. However, muscle and bone weigh more than fat, so BMI measurements can overestimate the danger for people with a muscular build or a larger frame. Conversely, BMI can underestimate health concerns in older adults and anyone who has lost muscle, according to the Harvard T.H. Chan School of Public Health in Boston.
Now, authors of a new study say a different approach to weight measurement may be a more accurate way to predict future health issues. Bioelectrical impedance analysis, or BIA, uses undetectable electric currents to measure not only the percentage of body fat but also lean muscle mass and water weight.
The technology works like this: You stand on metal plates on the machine while holding your hands or thumbs on another metal attachment held away from the body. Once started, the machine sends a weak electrical current through the body. Body fat, muscle and bone all have different electrical conductivity, so the machine uses algorithms to determine lean muscle mass, body fat percentage and water weight.
'We found body-fat percentage to be a stronger predictor of 15-year mortality risk in adults between the ages of 20 and 49 than BMI,' said Arch Mainous III, lead author of the study published Tuesday in the journal Annals of Family Medicine.
When it came to deaths from heart disease, people with high body fat as measured by BIA were 262% times more likely to die than people who had a healthy percentage of body fat, said Mainous, a professor and vice chair of research in community health and family medicine at the University of Florida School of Medicine.
'Now remember, using BMI did not flag any risk at all in this younger population, which isn't one we typically consider to be at high risk for heart disease,' said senior author Dr. Frank Orlando, a clinical associate professor of community health and family medicine at University of Florida Health.
'Think of the interventions we can do to keep them healthy when we know this early. I think it's a game-changer for how we should look at body composition,' Orlando said.
The problem with BMI
BMI is measured by dividing your weight by the square of your height. (If you are mathematically challenged like I am, the National Institutes of Health has a free calculator.)
In BMI world, a body mass between 18.5 and 24.9 is a healthy weight, between 25 and 29.9 is overweight, between 30 and 34.9 is obese, between 35 and 39.9 is class 2 obesity, and anything greater than 40 is 'severe' or class 3 obesity. People are considered underweight if their BMI is lower than 18.5.
Using BMI to measure health risk works — on a population level. Countless studies have shown that a greater BMI really does correlate with developing chronic diseases of all kinds — cancer, heart disease, type 2 diabetes, kidney and liver disease, and more.
Where BMI fails is at the patient level. Imagine a patient who is 'skinny fat' — thin on the outside but riddled with globs of fat wrapped around major organs on the inside. Your BMI would be fine even though your health was at risk.
'Those people are more likely to have nonalcoholic fatty liver disease, more likely to have elevated glucose, more likely to have elevated blood pressure, and more likely to have inflammation in general,' Mainous said.
All of these health issues can be treated, stopped and in some cases even reversed if caught early enough, he added.
While doctors are aware of the issues with BMI, many prefer it 'because it is cheap and easily put into practice,' Mainous said. 'They'd like to use a more direct measurement such as a DEXA scan, but those cost too much and are not widely available, so everyone falls back to the indirect measure of BMI.'
DEXA stands for dual-energy X-ray absorptiometry and is the gold standard for body mass analysis. Such machines can cost between US$45,000 and $80,000, so patients typically travel to a hospital or specialty center to get the scan, Orlando said. The cost to the patient can easily be $400 to $500 per scan, he said.
'However, we found the newer versions of bioelectrical impedance are pretty accurate, giving some valid and reliable results,' Orlando said.
One note — at-home based bioelectrical impedance products are not nearly as accurate, said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver.
'They can be affected a lot by how much body fluid you have, how hydrated you are,' said Freeman, who was not involved with the new research. 'At-home measurements will only give a ballpark — the clinic-based machines are more precise.'
Is it time for doctors to embrace body fat measurements?
The new study analyzed data on 4,252 men and women who participated in the 1999 to 2004 federal survey called NHANES, or the National Health and Nutrition Examination Survey, a yearly checkup of the nation's health.
Technicians measured each person's body composition, including height, weight and waist circumference. In addition, all participants underwent a clinic-based bioelectrical impedance analysis, which measures the body's resistance to electrical currents.
Researchers then compared that data with the National Death Index through 2019 to see how many people died. After adjusting for age, race and poverty status, the study found a BMI that labeled someone as obese was not associated with a statistically significant higher risk of death from any cause, when compared with those in healthy BMI range.
People with high body fat as measured by bioimpedance analysis, however, were 78% more likely to die from any cause, Mainous said. Measuring waist circumference was also helpful, but not as accurate as body mass.
Add that to the 262% higher chance of dying from heart disease found by the study, and it's a no-brainer for doctors to use bioelectrical impedance analysis on patients, Orlando said.
'Let's face it, the magnitude of risk this study shows is enormous,' Freeman said. 'It's scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years.'
The study shows how better weight measurements could easily become personalized medicine, Freeman added.
'Imagine you came into your doctor's office,' he said. 'They provided your body fat percentage and an individualized risk assessment. They talked to you about exercise and other lifestyle changes and referred you to a nutritionist.
'They gave you an opportunity to make these changes, and then if needed, helped you out with medication. If the medical profession did this and were able to save many more lives, that would be amazing.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
a day ago
- CBC
Regina couple's app teaches mindfulness to break the cycle of addiction
It began with moments of personal reflection. Adam Geiger had been battling a gambling addiction since he was a teenager. "I think it started innocently enough, with things like video games and whatnot," Geiger said. "Looking back, I remember myself being very anxious, always really trapped in my mind thinking of what other people thought of me." After decades of struggle, mindfulness and meditation helped him shift gears, allowing him to explore not just his behaviour, but the thoughts beneath it. "Looking at the nature of thought and what was going on, sort of beneath the surface level stuff," he said. In 2024, he and his partner Chelsea Galloway two decided to build a digital tool to support others facing similar struggles. "I think Adam and I both had this opportunity at the time to really be able to put ourselves into something that mattered to us personally," Galloway said. A year and a half later, their vision became reality with the launch of AlchemistOne, a mindfulness-focused recovery app designed to support people dealing with addictions. A shared mission born from experience Geiger's journey to AlchemistOne began decades ago, when an innocent love of video games and sports grew to compulsive gambling. "I made my first sports bet when I was 13 or 14," he said. "All those thoughts went away and it was very easy for me to escape into gambling." Temporary relief came with long-term consequences. Geiger said he spent more 20 years locked in a cycle of gambling addiction. Once he finally broke that cycle, the app seemed like a perfect opportunity to help others do the same. Galloway, the company's COO, brought both personal insight and business expertise to the project. "Addiction was just something that was really present in our lives," she said. "Adam had a really strong tech background. I had a pretty strong business background. So we came together to build the company." The pair spent months designing what would become AlchemistOne. What started as a two-person initiative now includes six full-time team members and a growing community of close to 6,000 downloads worldwide. A 3-pillar approach Geiger said that at its core, AlchemistOne is built around three key pillars of recovery: Mindfulness and meditation. Active reflection. Physical movement. Users can access a library of audio content, including guided meditations, podcast-style interviews and personal stories from people around the world who are in recovery. Geiger acknowledged an irony in people using the same phone or tablet that accessed gambling sites, social media or other addictive content as a tool for recovery. Instead of turning to a casino app or a harmful distraction, users can open AlchemistOne and engage in a quick mindfulness session. "I think often our phones and our computers are the things that we use to escape into and keeps us a lot of trouble," he said. "We definitely wanted to build that daily companion that lived in that same space that you maybe had some trouble before." Since the launch in April 2025, the response has been swift and steady the pair says. "It's really exciting that we see new members every five or 10 minutes jumping into the app and signing up," Galloway said. For both founders, the real win isn't downloads, it's impact. "We're getting that feedback from people who are saying, you know, this is resonating with me," Galloway said. "It's complicated, it's complex. And if we can just bring something to the table that helps people get through their day and potentially helps long lasting recovery, that's really the end goal."


National Post
a day ago
- National Post
Colby Cosh: The atomic bomb through Oppenheimer's eyes
Can it really be two years since Christopher Nolan's film 'Oppenheimer' became the old-school box-office sensation of summer 2023? Well, there you go, it must have been two years: even a journalist can do that much math. 'Oppenheimer,' which is reasonably scrupulous in its accuracy by cinema standards, continues to be fertile ground for discussion and memes. People will go on talking about the war and the command decision to bomb, but the drama of Los Alamos, N.M., is a distinctive, important historical phenomenon, a little nugget of uncanny magic rearranging human history at the outset of the Jet Age. Article content Article content A cult of wizards was assembled (on a mountaintop, loosely speaking) by a great empire: it was told to come up with a method to drop a sun on its enemies, and they succeeded. As Nolan's movie implies, almost every other thing that happened in the 20th century, including the actual use of the weapon, might be a footnote. Article content Article content Article content If you are suitably mesmerized by these events, one thing to remember is that the record of them is still incomplete. 'Oppenheimer' was made even though documentary material about, and by, J. Robert Oppenheimer is still becoming available to the public, as a new National Security Archive (NSA) release reminded us on Tuesday. The NSA maintains a 'briefing book' of primary sources on the bombings of Hiroshima and Nagasaki, and it makes periodic updates with newly declassified or rediscovered materials. The briefing book itself, built up over 20 years, is extensive enough to fertilize graduate-level papers on the decisions surrounding construction and use of the bomb. Article content Article content There are some fascinating new declassified documents in the 2025 update. One is a letter written in September 1944 by William S. Parsons, the navy officer who headed the ordnance group at Los Alamos. Parsons led the creation of the 'gun' design used for Little Boy, the bomb dropped on Hiroshima, and he would fly on the mission that delivered it. But he also had an administrative role as a voice of, and pair of eyes for, the professional military among the civilian boffins at Los Alamos. Article content Article content Parsons' letter is addressed to Maj.-Gen. Leslie Groves, overall boss of the Manhattan Project, and was delivered by Oppenheimer, which is why it sits in a file folder among the Oppenheimer Papers at the Library of Congress. Article content The letter is Parsons' rambling argument, extraordinary in historical retrospect, against any mere testing of a nuclear weapon. Plans for what became the Trinity test in the New Mexico desert were already coming into view, and the American high command was then still wondering whether to invite representatives of the Axis governments. Parsons points out morbidly that the most impressive test, the most convincing demonstration, would be to detonate the bomb 'one thousand feet over Times Square.' Short of that, he did not see the point of setting one off in the desert amid a few unoccupied temporary structures when it could just be dropped on an enemy. 'Even the crater would be disappointing.'


Globe and Mail
a day ago
- Globe and Mail
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025